BUZZ-Option Care Health surges after $5.8 billions privatization deal
路透社2026/10/06 14:17Latest developments on October 6 - ** Option Care Health (OPCH.O) shares surged 33% to $31.07 ** McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice will acquire OPCH for about $5.8 billions (including debt) (link) ** Option Care shareholders will receive $32.05 per share, representing a 37.1% premium over the company's most recent closing price ** McKesson will invest approximately $1.4 billions for a 49% stake and retains the right to acquire the remaining 51% from CD&R at a future date ** Leerink Partners analysts said the deal is "a logical adjacencies investment, helping McKesson further expand its presence across vertically integrated areas" ** The transaction is expected to complete in the first half of 2027, after which Option Care Health will become a private company ** McKesson shares edged up to $922.41 ** As of the previous trading day's close, OPCH had declined by 26.7% year-to-date
Latest Updates
October 6 - ** Option Care Health (OPCH.O) shares soared 33% to $31.07
** McKesson (MCK.N) and private equity firm Clayton Dubilier & Rice will acquire OPCH for about $5.8 billion (including debt) (link)
** Option Care shareholders will receive $32.05 per share, representing a 37.1% premium over the company’s most recent closing price
** McKesson will invest about $1.4 billion for a 49% stake and retains the right to acquire the remaining 51% from CD&R at a future date
** Analysts at Leerink Partners said the deal is “a logical adjacency investment that helps McKesson further expand its reach in vertical integration businesses”
** The transaction is expected to close in the first half of 2027, after which Option Care Health will become a private company
** McKesson shares edged up to $922.41
** As of the last trading day’s close, OPCH is down 26.7% year-to-date
(To assist non-native English speakers, Reuters has translated this report automatically into several other languages. Since automated translation may be incorrect or lack contextual accuracy, Reuters makes no guarantee as to the accuracy of the automated translation and provides it purely for readers’ convenience. Reuters accepts no liability for any damage or loss arising from the use of this automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan (JPM.US) Q3 revenue and EPS below expectations, fixed income trading decline drags performance
JPMorgan released its financial report for the third quarter of 2026.